Radiation After Surgery Keeps High Risk Prostate Cancer at Bay According to Large, Multi-Institutional Analysis
LOS ANGELES (Oct. 2007)—An analysis of data involving more than 2,000 patients from 17 U.S. institutions demonstrates that men with high-risk prostate cancer who receive radiation therapy after a prostatectomy were less likely to have a recurrence of disease. What's more, men whose cancer persists after surgery were less likely to see the cancer spread if they receive radiation (salvage therapy). These are the conclusions of a study presented today at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
"Our analysis gives us a robust picture of the national experience in treating these high-risk prostate cancers," said Eric M. Horwitz, MD - Chair, Radiation Oncology; Gerald E. Hanks Chair in Radiation Oncology, clinical director of the radiation oncology department at Fox Chase Cancer Center, Philadelphia, and lead author of the study.
For the study, data from 2,183 men who underwent radiation therapy after radical prostatectomy were available for analysis.
"This is the first time we've applied the new method of defining success to such a large sampling," explained Horwitz. "The results are even more dramatic in favor of post-operative radiation when compared to the old formula. Given our findings, I expect we'll see more men receive and benefit from radiation after prostatectomy for men with high-risk prostate cancer."
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.